SAN DIEGO – Biopharmaceutical companies and venture capitalists have become more likely in recent years to seek out and license drug “platform” technologies such as RNAi from universities, non-profit research institutes, and smaller biotechnology companies, a panel of tech-transfer experts said at a conference held here this week.